Under the agreement, Exact Sciences will pay Freenome an upfront cash payment of $75m that is payable by this November.

Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...

Exact Sciences beat Q2 expectations, raised its 2025 forecast, and secured U.S. rights to Freenome's CRC blood tests in a ...

Exact Sciences secures colorectal cancer test rights from Freenome in a $75M agreement with up to $700M milestone payouts.

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a ...

Brisbane, California Friday, August 8, 2025, 10:00 Hrs [IST] ...

Cathie Wood is one of the country's best known growth investors, but sometimes, she acts like an umbrella-toting value ...

The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...

Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

Colonoscopy prevalence increased from 19.5% in 2019 and 17.8% in 2021 to 27.7% in 2023, while stool-based testing increased ...